Skip to main content
Premium Trial:

Request an Annual Quote

Seraseq Circulating Tumor DNA v2 Reference Materials

SeraCare Life Sciences has launched a new set of ctDNA reference materials to aid development and validation of liquid biopsy assays. The new Seraseq Circulating Tumor DNA v2 reference materials were produced using a unique technology that produces a DNA fragment size-distribution which closely mimics native cfDNA, while decreasing DNA damage relative to ultrasonicated material, the company said.

The new product requires no special workflow considerations to generate informative data, and contains 40 somatic mutations, including important targets like BRAF V600E, KRAS G12D, and various EGFR alterations. Variants are present against a single well-characterized genomic background across a range of allele frequencies down to 0.125 percent, which ensures utility for assays with different limits of detection.

The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.